# US 2015/0105541 A1 · Antibody-active agent conjugates and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0105541 A1
- Document ID: US20150105541A1
- Status: Published application
- Kind: A1
- Application number: 14/517,616
- Filed: 2014-10-17
- Published: 2015-04-16
- Earliest claimed: 2011-05-08
- Assignees: LegoChem Biosciences, Inc.
- Applicants: Legochem Biosciences, Inc.
- Inventors: Yongzu Kim; Taekyo Park; Sungho Woo; Hyangsook Lee; Sunyoung Kim; Jongun Cho; Doohwan Jung; Youngun Kim; Hyunjin Kwon; Kyuman Oh; Yunseo Chung; Yun-Hee Park
- Web page: https://patentgrep.com/patent/US20150105541A1

## CPC

- C12Q 1/48: involving transferase
- A61K 47/549: {Sugars, nucleosides, nucleotides or nucleic acids}
- A61K 47/55: the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
- A61K 47/65: Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
- A61K 47/68031: {the drug being an auristatin}
- A61K 47/6811: {the drug being a protein or peptide, e.g. transferrin or bleomycin}
- A61K 47/6817: {Toxins}
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61K 47/6851: {the antibody targeting a determinant of a tumour cell}
- A61K 47/6855: {the tumour determinant being from breast cancer cell}
- A61K 47/6859: {the tumour determinant being from liver or pancreas cancer cell}
- A61K 47/6889: {Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment}
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 31/10: Antimycotics
- A61P 31/12: Antivirals
- A61P 33/00: Antiparasitic agents
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- C07K 16/2863: {against receptors for growth factors, growth regulators}
- C07K 16/32: against translation products of oncogenes
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The invention provides protein-active agent conjugates having an amino acid motif that can be recognized by an isoprenoid transferase. The invention also provides compositions containing the conjugates. The invention further provides methods for using the conjugates to deliver the active agent to a target cell, as well as methods for using the conjugates to treat a subject in need thereof (e.g., a subject in need of the active agent)

## Claims

### Claim 1

An antibody-active agent conjugate comprising:
(a) an antibody;
(b) at least one amino acid motif directly or indirectly linked to the antibody, wherein the amino acid motif is recognizable by an isoprenoid transferase;
(c) an isosubstrate directly linked to the at least one amino acid motif, wherein the isosubstrate contains a modification in a natural substrate of the isoprenoid transferase and contains at least one isoprenoid unit that is recognizable by the isoprenoid transferase; and
(d) at least one active agent directly or indirectly linked to the isosubstrate.

### Claim 2 (depends on 1)

The conjugate of claim 1, wherein the antibody comprises a modification selected from the group consisting of:
(a) deletion of at least one amino acid;
(b) addition of at least one amino acid; and
(c) a combination thereof.

### Claim 3 (depends on 1)

The conjugate of claim 1, wherein the antibody is
(a) selected from the group consisting of an intact polyclonal antibody, an intact monoclonal antibody, an antibody fragment, antibody analogs, a single chain Fv (scFv) mutant, a multispecific antibody, a bispecific antibody, a chimeric antibody, a humanized antibody, a human antibody, a naturally occurring antibody, a genetically modified immunoglobulin, and a fusion protein comprising an antigen determination portion of an antibody, or
(b) selected from the group consisting of Muromonab-CD3 Abciximab, Rituximab, Daclizumab, Palivizumab, Infliximab, Trastuzumab, Etanercept, Basiliximab, Gemtuzumab ozogamicin, Alemtuzumab, Ibritumomab tiuxetan, Adalimumab, Alefacept, Omalizumab, Efalizumab, Tositumomob-I131, Cetuximab, Bevacizumab, Natalizumab, Ranibizumab, Panitumumab, Eculizumab, Rilonacept, Certolizumab pegol, Romiplostim, AMG-531, CNTO-148, CNTO-1275, ABT-874, LEA-29Y, Belimumab, TACI-Ig, Second generation anti-CD20, ACZ-885, Tocilizumab, Atlizumab, Mepolizumab, Pertuzumab, Humax CD20, CP-675, 206, Ticilimumab, MDX-010, IDEC-114, Inotuzumab ozogamycin, HuMax EGFR, Aflibercept, VEGF Trap-Eye, HuMax-CD4, Ala-Ala, ChAg1yCD3, TRX4, Catumaxomab, IGN101, MT-201, Pregovomab, CH-14.18, WX-G250, AMG-162, AAB-001, Motavizumab, MEDI-524, efumgumab, Aurograb®, Raxibacumab, Third generation anti-CD20, LY2469298, Veltuzumab, Herceptin, and an antibody directed against c-Met.

### Claim 4 (depends on 1)

The conjugate of claim 1, wherein the antibody comprises (a) at least one light chain, (b) at least one heavy chain, or (c) two light chains and two heavy chains.

### Claim 5 (depends on 4)

The conjugate of claim 4, wherein one or more of the at least one light chain is/are directly or indirectly linked to the amino acid motif and the at least one heavy chain is/are directly or indirectly linked to the amino acid motif.

### Claim 6 (depends on 4)

The conjugate of claim 4, wherein one or more of the at least one heavy chain is/are directly or indirectly linked to the amino acid motif.

### Claim 7 (depends on 4)

The conjugate of claim 4, wherein one or both of the two light chains is/are directly or indirectly linked to the amino acid motif.

### Claim 8 (depends on 4)

The conjugate of claim 4, wherein one or both of the two heavy chains is/are directly or indirectly linked to the amino acid motif.

### Claim 9 (depends on 1)

The conjugate of claim 1, wherein the at least one amino acid motif is CAAX, XXCC, XCXC, or CXX, wherein C represents cysteine, A represents an aliphatic amino acid, and X represents an amino acid that determines a substrate specificity of the isoprenoid transferase.

### Claim 10 (depends on 1)

The conjugate of claim 1, wherein the at least one amino acid motif is (a) CAAX, and AAX is removed, (b) CVIM, or (c) CVLL.

### Claim 11 (depends on 1)

The conjugate of claim 1, wherein the at least one amino acid motif is directly or indirectly linked to the antibody at least one carboxy terminus of the antibody.

### Claim 12 (depends on 1)

The conjugate of claim 1, wherein the at least one amino acid motif is indirectly linked to the antibody via a spacer group.

### Claim 13 (depends on 12)

The conjugate of claim 12, wherein the spacer group comprises at least one amino acid.

### Claim 14 (depends on 12)

The conjugate of claim 12, wherein the spacer group comprises at least one glycine.

### Claim 15 (depends on 1)

The conjugate of claim 1, wherein the linkage between the isosubstrate and the at least one amino acid motif is formed via an enzymatic reaction catalyzed by the isoprenoid transferase.

### Claim 16 (depends on 1)

The conjugate of claim 1, wherein the isosubstrate is indirectly linked to the at least one active agent via at least one linker.

### Claim 17 (depends on 16)

The conjugate of claim 16, wherein the linker is a linear linker.

### Claim 18 (depends on 17)

The conjugate of claim 17, wherein the linear linker is directly linked to the at least one active agent or at least two different active agents.

### Claim 19 (depends on 16)

The conjugate of claim 16, wherein the linker is a linker having branches.

### Claim 20 (depends on 19)

The conjugate of claim 19, wherein one or more of the branches are directly linked to at least one of the active agents.

### Claim 21 (depends on 19)

The conjugate of claim 19, wherein at least two of the branches are directly linked to different active agents.

### Claim 22 (depends on 16)

The conjugate of claim 16, wherein the linker is a cleavable linker or a non-cleavable linker.

### Claim 23 (depends on 22)

The conjugate of claim 22, wherein the cleavable linker is selected from the group consisting of a chemically cleavable linker, an enzymatically cleavable linker, a hydrolysable linker, and a combination thereof.

### Claim 24 (depends on 23)

The conjugate of claim 23, wherein the enzymatically cleavable linker contains a peptide that can be cleaved by cathepsin B or a glucuronide that can be cleaved by β-glucuronidase.

### Claim 25 (depends on 1)

The conjugate of claim 1, wherein the at least one active agent is:
(a) a drug selected from the group consisting of erlotinib (TARCEVA), bortezomib (VELCADE), fulvestrant (FASLODEX), sutent (SU11248), letrozole (FEMARA), imatinib mesylate (GLEEVEC), PTK787/ZK 222584, oxaliplatin (Eloxatin), 5-fluorouracil (5-FU, leucovorin, rapamycin (Sirolimus, RAPAMUNE), lapatinib (TYKERB, GSK572016), lonafarnib (SCH 66336), sorafenib (BAY43-9006), gefitinib (IRESSA), AG1478, AG1571 (SU 5271), alkylating agents such as thiotepa and CYTOXAN® cyclophosphamide; alkyl sulfonates such as busulfan, improsulfan and piposulfan; aziridines such as benzodopa, carboquone, meturedopa, and uredopa; ethylenimine and methylamelamines including altretamine, triethylenemelamine, trietylenephosphoramide, triethiylenethiophosphoramide and trimethylolomelamine; acetogenins (especially, bullatacin and bullatacinone); camptothecin (inducing the synthetic analogue topotecan); bryostatin; callystatin; CC-1065 (including its adozelesin, carzelesin and bizelesin synthetic analogues); cryptophycins (particularly cryptophycin 1 and cryptophycin 8); dolastatin; duocarmycin (including the synthetic analogues, KW-2189 and CB1-TM1); eleutherobin; pancratistatin; sarcodictyin; spongistatin; nitrogen mustards such as chlorambucil, chlornaphazine, cholophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard; nitrousureas such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine, and ranimnustine; antibiotics such as the enediyne antibiotics (e.g, calicheamycin, especially calicheamycin gamma1 I and calicheamycin omegaI1 and dynemicin, inducing dynemicin A; bisphosphonate such as clodronate; esperamicin, neocarzinostatin chromophore and related chromoprotein enediyne antibiotic chromophores, aclacinomysins, actinomycin, antrmycin, azaserine, bleomycins, cactinomycin, carabicin, carninomycin, carzinophilin, chromomycins, dactinomycin, daunorubicin, detorubucin, 6-diazo-5-oxo-L-norleucine, ADRLIMYCIN® doxorubicin (including morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubucin, liposomal doxorubicin and deoxydoxorubicin), epirubicin, esorubicin, marcellomycin, mitomycins such as mitomycin C, mycophenolic acid, nogalamycin, olivomycins, peplomycin, potfiromycin, puromycin, quelamycin, rodorubicin, streptomigrin, streptozocin, tubercidin, ubenimex, zinostatin, and zorubicin; anti-metabolites such as 5-fluorouracil(5-FU); folic acid analogues such as denopterin, methotrexate, pteropterin, trimetrexate; purine analogs such as fludarabine, 6-mercaptopurine, thiamiprine, and thiguanine; pyrimidine analogs such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, and floxuridine; androgens such as calusterone, dromostanolone propionate, epitiostanol, mepitiostane, and testolactone; anti-adrenals such as aminoglutethimide, mitotane, and trilostane; folic acid replenisher such as folinic acid; aceglatone; aldophosphamide glycoside; aminolevulinic acid; eniluracil; amsacrine; bestrabucil; bisantrene; edatraxate; defofamine; demecolcine; diaziquone; elfornithine; elliptinium acetate; an epothilone; etoglucid; gallium nitrate; hydroxyurea; lentinan; lonidainine; maytansinoids such as maytansine and ansamitocins; mitoguazone; mitoxantrone; mopidanmol; nitraerine; pentostatin; phenamet; pirarubicin; losoxantrone; 2-ethylhydrazide; procarbazine; PSK® polysaccharide; razoxane; rhizoxin; sizofiran; spirogermanium; tenuazonic acid; triaziquone; 2,2′,2″-trichlorotriethylamine; trichothecenes (especially T-2 toxin, verracurin A, roridin A and anguidine); urethane; vindesine; dacarbazine; mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine; arabinoside (‘Ara-C’); cyclophosphamide; thiotepa; taxoids, e.g., TAXOL® paclitaxel; ABRAXANE™ cremophor-free, albumin-engineered nanoparticle formulation of paclitaxel (American Pharmaceutical Partners, Schaumber, Ill.), and TAXOTERE® doxetaxel; chloranbucil; gemcitabine; 6-thioguanine; mercaptopurine; platinum analogs such as cisplatin, carboplatin; vinblastine; platinum; etoposide, ifosfamide; mitoxantrone; vincristine; NAVELBINE® vinorelbine; novantrone; teniposide; edatrexate; daunomycin; aminopterin; xeloda; ibandronate; CPT-11; topoisomerase inhibitor RFS 2000; difluorometlhylornithine (DFMO); retinoids such as retinoic acid; capecitabine; and pharmaceutically acceptable salts, solvates, acids, or derivatives thereof;
(b) a cytokine selected from the group consisting of a monokine, a lympokine, a traditional polypeptide hormone, a growth hormone, human growth hormone, N-methionyl human growth hormone, bovine growth hormone, parathyroid hormone, thyroxine, insulin, proinsulin, relaxin, prorelaxin, a glycoprotein hormone, follicle stimulating hormone (FSH), thyroid stimulating hormone (TSH), luteinizing hormone (LH), hepatic growth factor fibroblast growth factor, prolactin, placental lactogen, tumor necrosis factor-α, tumor necrosis factor-β, mullerian-inhibiting substance, mouse gonadotropin-associated peptide, inhibin, activin, vascular endothelial growth factor, integrin, thrombopoietin (TPO), a nerve growth factor, NGF-β, platelet-growth factor, a transforming growth factor (TGF), TGF-α, TGF-β, insulin-like growth factor-I, insulin-like growth factor-II, erythropoietin(EPO), an osteoinductive factor, an interferon, interferon-α, interferon-β, interferon-γ, a colony stimulating factor (CSF), macrophage-CSF (M-CSF), granulocyte-macrophage-CSF (GM-CSF), granulocyte-CSF (G-CSF), an interleukin (IL), IL-1, IL-1α, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, a tumor necrosis factor, TNF-α,TNF-β, a polypeptide factor, LIF, kit ligand (KL), biologically active equivalents of a cytokine, and a combination thereof;
(c) a toxin selected from the group consisting of diphtheria toxin, botulium toxin, tetanus toxin, dysentery toxin, cholera toxin, α-amanitin, pyrrolobenzodiazepin derivatives, tetrodotoxin, brevetoxin, ciguatoxin, ricin, AM toxin, auristatin, tubulysin, geldanamycin, maytansinoid, calicheamycin, daunomycin, doxorubicin, methotrexate, vindesine, SG2285, dolastatin, dolastatin analog's auristatin, cryptophycin, camptothecin, a rhizoxin derivative, a CC 1065 analogue or derivative, duocarmycin, an enediyne antibiotic, esperamicin, epothilone, a toxoid, and a combination thereof;
(d) an affinity ligand selected from the group consisting of a substrate, an inhibitor, a stimulating agent, a neurotransmitter, a radioisotope, and a combination thereof;
(e) a detection moiety selected from the group consisting of radioactive labels, 32P, 35S, fluorescent dyes, electron dense reagents, enzymes, biotin, streptavidin, dioxigenin, haptens, proteins for which antisera or monoclonal antibodies are available, nucleic acid molecules with a sequence complementary to a target, and a combination thereof;
(f) a compound selected from the group consisting of an immunomodulatory compound, an anti-cancer agent, an anti-viral agent, an anti-bacterial agent, an anti-fungal agent, and an anti-parasitic agent, and a combination thereof
(g) an anti-hormonal agent that acts to regulate or inhibit hormone action on tumors such as anti-estrogens and selective estrogen receptor modulators (SERMs), including, for example, tamoxifen (including NOLVADEX® tamoxifen), raloxifene, droloxifene, 4-hydroxytamoxifen, trioxifene, keoxifene, LY117018, onapristone, and FAREATON® toremifene;
(h) an aromatase inhibitor that inhibits the enzyme aromatase, which regulates estrogen production in the adrenal glands, such as, for example, 4(5)-imidazoles, aminoglutethimide, MEGASE® megestrol acetate, AROMASIN® exemestane, FEMARA® letrozole, and ARIMIDEX® anastrozole;
(i) an anti-androgen such as flutamide, nilutamide, bicalutamide, leuprolide, and goserelin; as well as troxacitabine (a 1,3-dioxolane nucleoside cytosine analog);
(j) an aromatase inhibitor;
(k) a protein kinase inhibitor;
(l) a lipid kinase inhibitor;
(m) an antisense oligonucleotide, particularly those that inhibit expression of genes in signaling pathways implicated in aberrant cell proliferation, such as, for example, PKC-alpha, Raf, H-Ras;
(n) a ribozyme, for example, VEGF inhibitor such as ANGIOZYME ribozyme and HER2 expression inhibitors;
(o) a vaccine such as gene therapy vaccine; ALLOVECTIN® vaccine, LEUVECTIN vaccine and VAXID vaccine; PROLEUKIN®rlL-2; LURTOTECAN® topoisomerase 1 inhibitor; ABARELIX® rmRH; or
(p) an anti-angiogenic agent such as Bevacizumab (AVASTIN, Genentech); and pharmaceutically acceptable salts, solvates, acids, or derivatives thereof.

### Claim 26 (depends on 1)

The conjugate of claim 1, selected from the group consisting of Herceptin-LC-G7CVIM-BG-MMAF, Herceptin-LC-G7C-BG-MMAF, Herceptin-LC-G7CVIM-VC-MMAF-OMe, Herceptin-LC-GSC-VC-MMAF-OMe, Herceptin-LC-G7CVIM-BG-MMAE, and Herceptin-LC-G7C-BG-MMAE.

### Claim 27 (depends on 1)

The conjugate of claim 1, wherein the isosubstrate is linked to the at least one amino acid motif via an enzymatic reaction catalyzed by the isoprenoid transferase such that the antibody is not bound to a cell membrane via the enzymatic reaction.

### Claim 28

An antibody-active agent conjugate comprising:
(a) an antibody modified to include at least one amino acid motif, wherein the amino acid motif is recognizable by an isoprenoid transferase;
(b) an isosubstrate directly linked to the at least one amino acid motif, wherein the isosubstrate contains a modification in a natural substrate of the isoprenoid transferase and contains at least one isoprenoid unit that is recognizable by the isoprenoid transferase; and
(c) at least one active agent directly or indirectly linked to the isosubstrate.

### Claim 29 (depends on 28)

The conjugate of claim 28, wherein the antibody comprises an additional modification selected from the group consisting of:
(a) deletion of at least one amino acid;
(b) addition of at least one amino acid; and
(c) a combination thereof.

### Claim 30 (depends on 28)

The conjugate of claim 28, wherein the isosubstrate is linked to the at least one amino acid motif via an enzymatic reaction catalyzed by the isoprenoid transferase such that the antibody is not bound to a cell membrane via the enzymatic reaction.
